Rayne Rouce Explained
Rayne Rouce is an American pediatric hematologist-oncologist, physician scientist, and community leader who has authored over 200 original songs.[1]
Early life and education
Rouce attended Xavier University of Louisiana, a historically black college and university (HBCU) that has matriculated a record number of Black aspiring physicians to medical school.[2] Rouce earned her medical degree and completed her residency in Pediatrics at the University of Texas Medical Branch in Galveston. She completed her fellowship in pediatric hematology/oncology at Texas Children's Cancer Center.
Career
Rouce is Associate Professor of Pediatrics[3] at Baylor College of Medicine, where she leads the task force for promoting equity in cancer trials. She leads DEI programs for several scientific organizations.Rouce serves on the Board of Directors of the Leukemia & Lymphoma Society[4] and National Marrow Donor Program.[5] She directs research on CAR T cell therapy and stem cell transplantation.[6]
Community engagement
Rouce leads a weekend science program at Baylor. She spent years volunteering for the Periwinkle Foundation helping children, siblings, and families affected with cancer. She served on a medical mission to Bolivia.[7] Her fluency in Spanish has helped her serve patients and their families in Texas.[8] She advocates for dismantling barriers to access to transplantation and other cell therapies.[9]
After experiencing Hurricane Katrina while in college and losing her possessions during Hurricane Ike as a medical student in Galveston, Texas, Rouce organized relief efforts during both Hurricane Harvey and Hurricane Maria.[10]
Educational songs
Rouce raps her own educational songs as "Rizzo". She has performed her original science rap songs at national meetings, including the American Society of Hematology's ASH-a-Palooza each year since 2018. Her 2020 video performance, which can be viewed online, is accompanied by the ASH Blood Drop mascot and includes the lyrics:
What's a sickle cell, what does that entail?A gene, modified, stem cell?A congressional briefing with a strategic plan?Can we do it in this lifetime? Yes we can!The sky's the limit, benign or malignant!
In the song, she correctly predicted the development of gene therapy for sickle cell disease, namely Casgevy, which was FDA approved in 2023.[11] Her 2024 performance at the HOSA international leadership conference is also viewable online.[12]
Selected publications
- Rouce RH, Louis CU, Heslop HE . Epstein-Barr virus lymphoproliferative disease after hematopoietic stem cell transplant . Curr Opin Hematol . 21 . 6 . 476–81 . November 2014 . 25159713 . 4257464 . 10.1097/MOH.0000000000000083 .
- Rouce RH . More than Memory: Potential of Adaptive Natural Killer Cells . Biol Blood Marrow Transplant . 21 . 9 . 1534–6 . September 2015 . 26211986 . 10.1016/j.bbmt.2015.07.014 . free .
- Rouce RH, Shaim H, Sekine T, Weber G, Ballard B, Ku S, Barese C, Murali V, Wu MF, Liu H, Shpall EJ, Bollard CM, Rabin KR, Rezvani K . The TGF-β/SMAD pathway is an important mechanism for NK cell immune evasion in childhood B-acute lymphoblastic leukemia . Leukemia . 30 . 4 . 800–11 . April 2016 . 26621337 . 4823160 . 10.1038/leu.2015.327 .
- Rezvani K, Rouce RH . The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer . Front Immunol . 6 . 578 . 2015 . 26635792 . 4648067 . 10.3389/fimmu.2015.00578 . free .
- Rouce RH, Heslop HE . Forecasting Cytokine Storms with New Predictive Biomarkers . Cancer Discov . 6 . 6 . 579–80 . June 2016 . 27261481 . 4894532 . 10.1158/2159-8290.CD-16-0493 .
- Rouce RH, Sharma S, Huynh M, Heslop HE . Recent advances in T-cell immunotherapy for haematological malignancies . Br J Haematol . 176 . 5 . 688–704 . March 2017 . 27897332 . 5318250 . 10.1111/bjh.14470 .
- Rouce RH, Heslop HE . Equal opportunity CAR T cells . Blood . 129 . 25 . 3275–3277 . June 2017 . 28642356 . 5482104 . 10.1182/blood-2017-04-779983 .
- Doherty E, Rouce RH . Primed to Kill: CTV-1 Stimulated Haploidentical Natural Killer Cells for Consolidation of AML . Biol Blood Marrow Transplant . 24 . 8 . 1533–1535 . August 2018 . 29933070 . 10.1016/j.bbmt.2018.06.019 . free .
- Sharma S, Rouce RH . Are we there yet? The never-ending quest for an Epstein-Barr virus vaccine . J Clin Invest . 129 . 5 . 1836–1838 . April 2019 . 30985295 . 6486379 . 10.1172/JCI128370 .
- Steffin DH, Hsieh EM, Rouce RH . Gene Therapy: Current Applications and Future Possibilities . Adv Pediatr . 66 . 37–54 . August 2019 . 31230699 . 10.1016/j.yapd.2019.04.001 .
- Rouce RH . The earlier the better: timely mitigation of CRS . Blood . 134 . 24 . 2119–2120 . December 2019 . 31830277 . 10.1182/blood.2019003618 .
- Hsieh EM, Rouce RH . Chimeric antigen receptor T cells for mature B-cell lymphoma and Burkitt lymphoma . Hematology Am Soc Hematol Educ Program . 2020 . 1 . 487–493 . December 2020 . 33275669 . 7727550 . 10.1182/hematology.2020000133 .
- Rouce RH, Scherer L . Reverse translational studies inform dual-targeted CAR T-cell design . Blood . 140 . 5 . 409–410 . August 2022 . 35925644 . 10.1182/blood.2022016928 .
- Rouce RH, Nemecek E . Access offsets poverty in quest for CAR T cells . Blood . 141 . 6 . 558–560 . February 2023 . 36757731 . 10.1182/blood.2022018552 .
- Scherer LD, Rouce RH . Targeted cellular therapy for treatment of relapsed or refractory leukemia . Best Pract Res Clin Haematol . 36 . 3 . 101481 . September 2023 . 37612000 . 10.1016/j.beha.2023.101481 .
- Badr H, Rouce R, Scheurer ME, Lulla P, Mims M, Reddy P . Bringing CART therapy trials to underserved populations . Cancer Cell . 41 . 12 . 2007–2010 . December 2023 . 37890490 . 11146682 . 10.1016/j.ccell.2023.10.002 .
- Ma R, Woods M, Burkhardt P, Crooks N, van Leeuwen DG, Shmidt D, Couturier J, Chaumette A, Popat D, Hill LC, Rouce RH, Thakkar S, Orozco AF, Carisey AF, Brenner MK, Mamonkin M . Chimeric antigen receptor-induced antigen loss protects CD5.CART cells from fratricide without compromising on-target cytotoxicity . Cell Rep Med . 5 . 7 . 101628 . July 2024 . 38986621 . 11293353 . 10.1016/j.xcrm.2024.101628 .
- Mackall CL, Bollard CM, Goodman N, Carr C, Gardner R, Rouce R, Sotillo E, Stoner R, Urnov FD, Wayne AS, Park J, Kohn DB . Enhancing pediatric access to cell and gene therapies . Nat Med . 30 . 7 . 1836–1846 . July 2024 . 38886624 . 10.1038/s41591-024-03035-1 .
- Rouce RH, Porteus MH . Cell and gene therapy accessibility . Science . 385 . 6708 . 475 . August 2024 . 39088615 . 10.1126/science.ads0252 . 2024Sci...385..475R .
Notes and References
- Web site: Phifer . Andy . 'Swag worthy' doctor splits time between patients, rap music . Baylor College of Medicine . 4 September 2024 . February 3, 2021.
- Web site: Inspiring Lyrics Help Fight Childhood Cancer . American Society of Hematology . 5 September 2024.
- Web site: Rayne H. Rouce, MD: Cancer and Blood Disorders . Texas Children's Hospital . 5 September 2024.
- Web site: The Leukemia & Lymphoma Society Welcomes Five Members to its Board of Directors . Leukemia & Lymphoma Society . 5 September 2024 . July 1, 2024.
- Web site: Board of Directors: Rayne Rouce, MD . NMDP . 8 September 2024.
- Web site: Scott . Ryan . Tisagenlecleucel Climbs into Earlier Lines of Therapy for Pediatric R/R B-ALL . Onc Live . 5 September 2024 . September 4, 2024.
- Web site: Interview With 2016 ASH-AMFDP Recipient Rayne H. Rouce, MD . American Society of Hematology . 4 September 2024 . June 28, 2016.
- Web site: "New Frontiers of Cancer Cell and Gene Therapy: Is the Future Now?" . NIH VideoCast CCR Grand Rounds . NIH . 5 September 2024 . May 17, 2024.
- Web site: Rouce . Rayne . BLOG: Creating systemic change with the ASTCT-NMDP ACCESS Initiative . Healio . 5 September 2024 . Jan 31, 2023.
- News: Bagley . Allison . Physician Rayne Rouce activated social network to rescue families, gather donations . 4 September 2024 . Houston Chronicle . May 10, 2018.
- Vertex and CRISPR Therapeutics Announce US FDA Approval of Casgevy (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease . Vertex Pharmaceuticals . Business Wire . 8 December 2023 . 21 September 2024 . 9 December 2023 . https://web.archive.org/web/20231209193910/https://www.businesswire.com/news/home/20231208951733/en/Vertex-and-CRISPR-Therapeutics-Announce-US-FDA-Approval-of-CASGEVY%E2%84%A2-exagamglogene-autotemcel-for-the-Treatment-of-Sickle-Cell-Disease . live .
- News: Kigera . Noni . HOSA Alumna Dr. Rayne Rouce Engages and Inspires with Her Science Rap at the 2024 ILC . 5 September 2024 . HOSA Future Health Professionals . July 23, 2024.